



(51) International Patent Classification:

C07D 401/14 (2006.01) A61K 31/4418 (2006.01)
 C07D 401/04 (2006.01) A61K 31/444 (2006.01)
 C07D 409/04 (2006.01) A61K 31/506 (2006.01)
 C07D 409/14 (2006.01) A61P 3/00 (2006.01)
 C07D 417/14 (2006.01) A61P 9/00 (2006.01)

(21) International Application Number:

PCT/US2015/018874

(22) International Filing Date:

5 March 2015 (05.03.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/949,506 7 March 2014 (07.03.2014) US

(71) Applicant: BRISTOL-MYERS SQUIBB COMPANY
 [US/US]; Route 206 and Province Line Road, Princeton,
 New Jersey 08543 (US).

(72) Inventors: MENG, Wei; c/o Bristol-Myers Squibb Com-
 pany, 311 Pennington Rocky Hill Road, Pennington, New
 Jersey 08534 (US). ZHAO, Guohua; c/o Bristol-Myers
 Squibb Company, 311 Pennington Rocky Hill Road, Pen-
 nington, New Jersey 08534 (US).

(74) Agents: JACOBSEN, Barry H. et al.; Bristol-Myers
 Squibb Company, Route 206 and Province Line Road,
 Princeton, New Jersey 08543 (US).

(81) Designated States (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
 SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
 kind of regional protection available): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
 TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
 LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
 GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
 patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
 earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) Title: DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS



(57) Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.